Is Wall Street Bullish or Bearish on Cooper Companies Stock?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 28 2024
0mins
Source: NASDAQ.COM
Company Overview: The Cooper Companies, Inc., a leading medical device firm based in California, specializes in contact lenses and surgical products, with a market cap of $20.6 billion; however, its stock has underperformed compared to the broader market over the past year.
Stock Performance and Analyst Ratings: Following strong Q3 earnings that exceeded expectations, COO's stock rose 11.8%, and analysts maintain a consensus rating of "Strong Buy," with a mean price target suggesting potential upside from current levels.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COO
Wall Street analysts forecast COO stock price to rise
12 Analyst Rating
7 Buy
4 Hold
1 Sell
Moderate Buy
Current: 66.920
Low
73.00
Averages
90.33
High
100.00
Current: 66.920
Low
73.00
Averages
90.33
High
100.00
About COO
The Cooper Companies, Inc. is a global medical device company. The Company operates in two business units: CooperVision and CooperSurgical. CooperVision segment is involved in the contact lens industry. CooperSurgical segment is involved in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. CooperVision’s products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys. CooperSurgical’s portfolio includes INSORB, Lone Star, and the Doppler Blood Flow Monitor. It also offers a suite of single-use cordless surgical retractors with an integrated multi-light-emitting diode (LED) light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Positive Outlook for Medical Supply Industry
- Industry Growth Drivers: The global medical supplies market is projected to reach $163.5 billion by 2027, with a CAGR of 3.4%, indicating sustained growth driven by an aging population and innovation, benefiting companies like Cardinal Health and Becton, Dickinson.
- Technological Innovations: The healthcare sector is transitioning to digital-first operating models with AI integration, where automation tools enhance efficiency and reduce administrative burdens, thereby supporting predictive care delivery and improving patient engagement.
- Shifting Market Demand: The U.S. dental equipment market is structurally supported by demographic aging and rising disease prevalence, with the 65+ population driving increased procedure volumes and equipment utilization, reflecting a strong demand for high-quality healthcare services.
- Competition and Challenges: Despite the optimistic outlook, the industry faces challenges from procurement pressures in China, inflation, and regulatory uncertainties, necessitating companies to diversify sourcing and optimize supply chains to maintain competitive positioning.
See More
CooperVision Launches Sustainability Platform to Enhance Eco-Friendly Practices
- Sustainability Commitment: CooperVision's launch of the MADE BETTER™ Promise aims to reduce the carbon footprint of its MyDay® daily disposable contact lenses through smarter choices and sustainable manufacturing processes, enhancing brand image and meeting eco-conscious consumer demands.
- Plastic Neutrality Program: The company has partnered with Plastic Bank to successfully recycle over 659 million plastic bottles, demonstrating its proactive contribution to reducing ocean plastic pollution while creating economic benefits for communities in participating countries.
- Innovative Material Use: The MADE BETTER™ Innovation program incorporates ISCC PLUS-certified lower-carbon plastics and aluminum, which reduces packaging carbon emissions for MyDay® products, thereby enhancing their market competitiveness.
- Production Efficiency Improvement: At its Puerto Rico manufacturing facility, the implementation of combined heat and power technology has reduced greenhouse gas emissions per lens by approximately 30% compared to 2021, not only improving production efficiency but also aligning with global environmental trends.
See More
Telix Pharmaceuticals Appoints New Non-Executive Directors
- Board Expansion: Telix Pharmaceuticals announces the appointment of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, aimed at enhancing governance and financial oversight to support the company's strategic development in the global biopharmaceutical sector.
- Rivas's Background: Maria Rivas brings over 25 years of clinical development and commercialization experience, having served as Chief Medical Officer at Pfizer, where she oversaw the launch of multiple blockbuster medical products, and her expertise is expected to bolster Telix's capabilities in oncology and rare diseases.
- Jellison's Experience: William Jellison has over 30 years of corporate finance leadership experience, including serving as CFO of Stryker Corporation, where he managed international finance and M&A, and his financial acumen will provide critical strategic support for Telix.
- Strategic Implications: This board expansion aligns with Telix's evolution into a global commercial-stage biopharmaceutical company, reflecting the company's commitment to enhancing governance structures and increasing market competitiveness, which is expected to drive long-term growth in the biopharmaceutical industry.
See More
Telix Pharmaceuticals Appoints New Non-Executive Directors
- Board Expansion: Telix Pharmaceuticals announces the appointment of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, aimed at enhancing governance and financial oversight to support the company's strategic development in the global biopharmaceutical sector.
- Maria Rivas Background: Rivas brings over 25 years of clinical development and commercialization experience, having served as Chief Medical Officer at Pfizer, overseeing the launch of multiple blockbuster drugs, which will provide critical support for Telix's product development and market strategies.
- William Jellison Credentials: Jellison has over 30 years of corporate finance experience in large regulated environments, previously serving as CFO of Stryker, managing international finance and M&A, and his financial management expertise will enhance Telix's capital allocation efficiency.
- Strategic Implications: This board expansion aligns with Telix's evolution as a dual-listed global commercial-stage biopharmaceutical company, reflecting the company's commitment to improving governance structures and market competitiveness, which is expected to drive future business growth.
See More
TELIX ENHANCES BOARD WITH NEW DIRECTOR APPOINTMENTS
New Director Appointments: Telix has strengthened its board by appointing additional directors to enhance governance and strategic oversight.
Focus on Growth: The new appointments are part of Telix's strategy to support its growth initiatives and expand its operational capabilities.
See More
S&P 500 Futures Drop in Pre-Market Trading; Piper Sandler and Intercorp Financial Services at the Forefront
Market Opening: U.S. stock markets are set to open in two hours.
Piper Sandler Performance: Piper Sandler Cos. (PIPR) saw an 11.0% increase in pre-market trading.
Intercorp Financial Services Performance: Intercorp Financial Services Inc. (IFS) experienced a 9.2% rise in pre-market trading.
Overall Market Sentiment: The pre-market gains indicate positive sentiment ahead of the market opening.
See More
Positive Outlook for Medical Supply Industry
- Industry Growth Drivers: The global medical supplies market is projected to reach $163.5 billion by 2027, with a CAGR of 3.4%, indicating sustained growth driven by an aging population and innovation, benefiting companies like Cardinal Health and Becton, Dickinson.
- Technological Innovations: The healthcare sector is transitioning to digital-first operating models with AI integration, where automation tools enhance efficiency and reduce administrative burdens, thereby supporting predictive care delivery and improving patient engagement.
- Shifting Market Demand: The U.S. dental equipment market is structurally supported by demographic aging and rising disease prevalence, with the 65+ population driving increased procedure volumes and equipment utilization, reflecting a strong demand for high-quality healthcare services.
- Competition and Challenges: Despite the optimistic outlook, the industry faces challenges from procurement pressures in China, inflation, and regulatory uncertainties, necessitating companies to diversify sourcing and optimize supply chains to maintain competitive positioning.
See More
CooperVision Launches Sustainability Platform to Enhance Eco-Friendly Practices
- Sustainability Commitment: CooperVision's launch of the MADE BETTER™ Promise aims to reduce the carbon footprint of its MyDay® daily disposable contact lenses through smarter choices and sustainable manufacturing processes, enhancing brand image and meeting eco-conscious consumer demands.
- Plastic Neutrality Program: The company has partnered with Plastic Bank to successfully recycle over 659 million plastic bottles, demonstrating its proactive contribution to reducing ocean plastic pollution while creating economic benefits for communities in participating countries.
- Innovative Material Use: The MADE BETTER™ Innovation program incorporates ISCC PLUS-certified lower-carbon plastics and aluminum, which reduces packaging carbon emissions for MyDay® products, thereby enhancing their market competitiveness.
- Production Efficiency Improvement: At its Puerto Rico manufacturing facility, the implementation of combined heat and power technology has reduced greenhouse gas emissions per lens by approximately 30% compared to 2021, not only improving production efficiency but also aligning with global environmental trends.
See More
Telix Pharmaceuticals Appoints New Non-Executive Directors
- Board Expansion: Telix Pharmaceuticals announces the appointment of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, aimed at enhancing governance and financial oversight to support the company's strategic development in the global biopharmaceutical sector.
- Rivas's Background: Maria Rivas brings over 25 years of clinical development and commercialization experience, having served as Chief Medical Officer at Pfizer, where she oversaw the launch of multiple blockbuster medical products, and her expertise is expected to bolster Telix's capabilities in oncology and rare diseases.
- Jellison's Experience: William Jellison has over 30 years of corporate finance leadership experience, including serving as CFO of Stryker Corporation, where he managed international finance and M&A, and his financial acumen will provide critical strategic support for Telix.
- Strategic Implications: This board expansion aligns with Telix's evolution into a global commercial-stage biopharmaceutical company, reflecting the company's commitment to enhancing governance structures and increasing market competitiveness, which is expected to drive long-term growth in the biopharmaceutical industry.
See More
Telix Pharmaceuticals Appoints New Non-Executive Directors
- Board Expansion: Telix Pharmaceuticals announces the appointment of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, aimed at enhancing governance and financial oversight to support the company's strategic development in the global biopharmaceutical sector.
- Maria Rivas Background: Rivas brings over 25 years of clinical development and commercialization experience, having served as Chief Medical Officer at Pfizer, overseeing the launch of multiple blockbuster drugs, which will provide critical support for Telix's product development and market strategies.
- William Jellison Credentials: Jellison has over 30 years of corporate finance experience in large regulated environments, previously serving as CFO of Stryker, managing international finance and M&A, and his financial management expertise will enhance Telix's capital allocation efficiency.
- Strategic Implications: This board expansion aligns with Telix's evolution as a dual-listed global commercial-stage biopharmaceutical company, reflecting the company's commitment to improving governance structures and market competitiveness, which is expected to drive future business growth.
See More
TELIX ENHANCES BOARD WITH NEW DIRECTOR APPOINTMENTS
New Director Appointments: Telix has strengthened its board by appointing additional directors to enhance governance and strategic oversight.
Focus on Growth: The new appointments are part of Telix's strategy to support its growth initiatives and expand its operational capabilities.
See More
S&P 500 Futures Drop in Pre-Market Trading; Piper Sandler and Intercorp Financial Services at the Forefront
Market Opening: U.S. stock markets are set to open in two hours.
Piper Sandler Performance: Piper Sandler Cos. (PIPR) saw an 11.0% increase in pre-market trading.
Intercorp Financial Services Performance: Intercorp Financial Services Inc. (IFS) experienced a 9.2% rise in pre-market trading.
Overall Market Sentiment: The pre-market gains indicate positive sentiment ahead of the market opening.
See More
